The porphyrias are a group of inborn or acquired disorders of haem synthesis that can result in neurovisceral or dermatological symptoms. Diagnosis is usually made using a combination of clinical presentation and biochemical parameters. This case report describes a 25-year-old woman clinically presenting with a rash and then found to have elevated porphobilinogen concentrations in her urine. The initial presumptive diagnosis of variegate porphyria was not supported by analysis of her plasma, urine and faeces, which suggested a combination of acute intermittent porphyria and porphyria cutanea tarda. Sequencing of the hydroxymethylbilane synthase and uroporphyrinogen decarboxylase genes confirmed the relatively rare diagnosis of dual porphyria, and revealed a novel uroporphyrinogen decarboxylase mutation.
Introduction
The porphyrias are a family of nine inherited and acquired partial de¢ciencies of haem biosynthetic enzymes. 1 They can be classi¢ed as hepatic or erythroid, depending on the main site of expression of the enzyme de¢ciency. Porphyria can result in recurrent attacks of neurovisceral symptoms, chronic cutaneous symptoms or a combination of both, determined by the level of the metabolic block. 1, 2 Laboratory diagnosis of porphyria is based on the pattern of various metabolic intermediates measured in urine, faeces and red cells. Urinary porphobilinogen (PBG) and aminolevulinic acid (ALA) are often elevated in the urine during acute neurovisceral 'attacks', and the activity of hydroxymethylbilane synthase is easily measured in red cells. 2, 3 Enzyme activities for the other porphyrias require more technically demanding assays, although a speci¢c diagnosis can usually be made based on the pattern of porphyrins --including protoporphyrins, uroporphyrins and coproporphyrins --in red cells, plasma, urine and faeces. 1, 3, 4 Prevalence varies between each individual porphyria and geographical location. Porphyria cutanea tarda (PCT) is relatively common, with thousands of cases described. It is caused by either inherited mutations or acquired defects in the uroporphyrinogen decarboxylase (UROD) enzyme. 1, 5 In contrast, the other porphyrias are exclusively hereditary and generally have a prevalence of less than one per hundred thousand. An exception to this is variegate porphyria (VP) in the South African population, where a founder mutation means that VP is more common. 6, 7 'Dual porphyria' caused by defects in two separate haem synthetic enzymes is very rare, and there have only been a few case reports in the literature. 8, 9 We present a case of dual acute intermittent porphyria (AIP) and PCT. Although a similar dual porphyria has been previously described, 10 this is the ¢rst case, to our knowledge, to be con¢rmed by the presence of mutations in the UROD and hydroxymethylbilane synthase (HMBS) genes.
Case report
A 25-year-old Caucasian woman presented to her general practitioner with a bullous rash in sun-exposed areas, which developed after she commenced the oral contraceptive pill. She denied any personal history of neurological or visceral attacks and any family history of neurovisceral or cutaneous symptoms. On examination, her rash was thought to be typical of that caused by a cutaneous porphyria, and urine, faeces and blood samples were sent to us for analysis.
Liver function tests and iron studies were normal, and mutational analysis showed she was homozygous for the p.H63D hereditary haemochromatosis mutation; p.C282Y was absent.
Random total urinary porphyrins were 10.3 mmol/L (0--0.3), or 1.94 mmol/mmol creatinine (o0.035) by spectrophotometry.
2 ALA was 43 mmol/L (0.8--34.3) and PBG was 67 mmol/L (0--8.8), as determined by column extraction and reaction with Erlich's reagent, absorbance measured at 553 nm (Bio-Rad Laboratories). The patient ceased the oral contraceptive pill and her rash improved.
The clinical presentation and elevated PBG were consistent with a diagnosis of VP, but plasma emission £uorescence spectroscopy showed an emission peak at 621nm rather than 626 nm, which is the expected value in VP due to the presence of the porphyrin peptide complex. 2 Faecal and urinary porphyrins were fractionated and qualitatively analysed by HPLC using a reverse-phase C18 column with £uorescent detection. 11 Faecal total porphyrins were 623 mmol per kg dry weight (0--200), with a pattern of elevated isocoproporphyrin (12.1% of total), 7-carboxylic (9.5%) and coproporphyrin (10.1%) with a normal C3/C1 ratio of 1.0. The presentation of rash and elevated urine PBG also introduced the di¡erential diagnosis of coproporphyria, although the normal C3/C1 ratio excludes this. Analysis of the urine sample revealed a pattern of elevated 7-carboxylic porphyrins (29.2% of total) and uroporphyrin (U1: 35.5%; U3: 23.0% of total) with an additive total of 87.7%. Therefore, the HPLC pro¢le appeared to be supportive of a diagnosis of PCT. Because urinary ALA and PBG were elevated, the red cell activity of HMBS was measured and found to be approximately 50% of normal at 10.9 mmol/L erythrocytes/h (14--30). 12 Our range for red cell HMBS activity (14--30) is derived from the in-house study of normal subjects. Taken together, the clinical and biochemical data are strongly suggestive of a dual porphyria in this patient (i.e. PCT co-existent with AIP). In order to determine the molecular basis of these enzyme defects, each exon of the UROD and HMBS genes was ampli¢ed by PCR and sequenced. DNA was extracted from peripheral blood on an automated liquid handling platform using the AGOWAmag Maxi DNA Isolation Kit (Agowa), according to manufacturer's instructions. Exons 1--15 of HMBS were ampli¢ed using a previously published method, 13 but omitting the gas chromatography clamps from the primers. Exons 1--12 of UROD were ampli¢ed using primers obtained from the Exon Locator and eXtractor for Resequencing (ELXR) website. 14 Polymerase chain reaction (PCR) cycling was carried out on an Eppendorf MasterCycler Gradient thermocycler (Eppendorf). The PCR program for the UROD amplicons consisted of 941C for 2 min, followed by 30 cycles of 941C for 20 s, 601C for 15 s and 651C for 30 s, and a ¢nal 2 min step at 651C. PCR reaction mixes for UROD consisted of 2.5 mL HotMaster PCR bu¡er (Eppendorf), 0.2 mM of each dNTP, 0.75 mL of 10 mM forward and reverse primers and 0.2 U of HotMaster Taq (Eppendorf). PCR products were puri¢ed using the Amicon MultiScreen-PCR 96-Well Filtration System (MANU030, Amicon) according to manufacturer's instructions, and sequenced in both forward and reverse directions using the ABI PRISM dye terminator cycle sequencing kit v3.0, with migration and detection on an ABI 3100 Avant electrophoresis system (Applied Biosystems).
Sequencing revealed the presence of a heterozygous inactivating mutation in each gene. The mutation in HMBS, c.422 þ1G4T, alters the invariant 5' splice donor site of intron seven, and is predicted to interrupt normal splicing. It has previously been reported in a family with AIP. 15 The mutation in UROD, g.2187_2188insTT, is novel. It is a two base insertion in exon seven of the UROD gene, which would be predicted to result in a shift in the reading frame of the messenger RNA. This in turn would probably cause nonsense-mediated decay of the mRNA, and production of a truncated protein from any translated mRNA. A similar mutation, consisting of the insertion of a single thymidine in the same position, has previously been reported. 16 Electropherograms demonstrating each mutation are shown in Figure 1 .
Discussion
This report describes a patient with dual acute intermittent porphyria and porphyria cutanea tarda, and is the ¢rst such reported case in which mutations in both UROD and HMBS genes have been delineated by molecular analysis. Establishing the molecular basis of AIP and PCT in this patient allows cascade testing of her relatives for carriage of one or both mutations. Although these disorders are dominantly inherited, their penetrance is relatively low. Biochemical indices are not always abnormal in asymptomatic mutation carriers. 2 However, such individuals are still at risk of developing symptoms if exposed to certain environmental agents, such as iron overload, oestrogen and alcohol in the case of PCT, and speci¢c medications in the case of AIP, VP and hereditary coproporphyria. 1, 6 Mutation testing allows advice to be given regarding the risk of developing AIP, PCT, or both, and which exposures should be avoided. It is interesting to note that this patient was homozygous for the p.H63D HFE mutation. Of HFE mutations, C282Y is a well-known risk factor for development of PCT, 5, 17 either in the homozygous state or as a compound heterozygote with H63D. H63D homozygosity, however, is not normally associated with iron overload. 18 Our case had a ferritin of 113 mg/L (20--200), thus was not iron overloaded. The rash in this patient was probably precipitated by the oral contraceptive pill, which is a well-known precipitant of PCT.
This patient has an interesting UROD mutation. The mutation g.2187_2188insTT is predicted to cause a frame-shift and therefore will act as a null allele for UROD. Although this mutation has not been reported previously, an insertion of a single thymidine in the same region of exon seven has occurred in at least one other family. 16 The insertions both follow a run of three consecutive thymidine nucleotides. It is possible that this region of exon seven is a minor 'hot spot' for insertional mutations (for example by polymerase slippage), by virtue of the run of three thymidines and the surrounding sequence structure.
Finally, this case demonstrates the utility of thorough biochemical analysis in cases of suspected porphyria, and the advantages o¡ered by molecular testing. The HMBS enzyme activity and pattern of metabolites elevated in urine, plasma and faeces clearly demonstrated combined features of PCT and AIP. Further UROD enzyme analysis could have potentially been carried out (by a referral laboratory), but this was unnecessary here because molecular testing con¢rmed the diagnosis of dual porphyria. This illustrates the utility of mutation analysis in the modern approach to the diagnosis of porphyria.
